Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer

Gynecologic Oncology

Volumn 82, Issue 2, 2001, Pages 291-298

  Lengyel, Ernst ^a,c   Schmalfeldt, Barbara ^a   Konik, Elisabeth ^a   Späthe, Kerstin ^a   Härting, Kathrin ^a   Fenn, Anke ^a   Berger, Ursula ^a   Fridman, Rafael ^b   Schmitt, Manfred ^a   Prechtel, Dieter ^a   Kuhn, Walther ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Matrix metalloproteinase 2; Matrix metalloproteinase 9; Ovarian cancer; Prognosis; Zymography

Indexed keywords

GELATIN; GELATINASE A; GELATINASE B;

ADULT; ADVANCED CANCER; AGE; AGED; ARTICLE; ASCITES; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CANCER; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; ZYMOGRAPHY;

EID: 0034909346     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2001.6243     Document Type: Article

References (38)

1. The biology of ovarian cancer
2. Factors in the causation and incidence of ovarian cancer
3. The role of proteolytic enzymes in the pathology of epithelial ovarian carcinoma
4. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc
5. General mechanisms of metastasis
6. Matrix metalloproteinases
7. Matrix metalloproteinase degradation of extracellular matrix: Biological consequences
8. Matrix metalloproteinases: Biologic activity and clinical implications
9. Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells
10. Expression of genes encoding type IV collagen-degrading metalloproteinases and tissue inhibitors of metalloproteinases in various human tumor cells
11. Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma
12. Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer
13. Matrix metalloproteinases in cancer: Prognostic markers and targets for therapy
14. Proteases as prognostic markers in cancer
15. Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9
16. Assay of matrix metalloproteinases types 1, 2, 3 and 9 in breast cancer
17. Prognostic relevance of MMP-2 (72-kD collagenase IV) in gastric cancer
18. Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: Purification of matrix metalloproteinase 2
19. Fibronectin secretion from human peritoneal tissue induces Mr 92,000 type IV collagenase expression and invasion in ovarian cancer cell lines
20. Expression and activity of MMPs and their regulators in ovarian cancer
21. The influence of upper abdominal surgery on perioperative morbidity and mortality in patients with advanced ovarian cancer FIGO III and FIGO IV
22. Involvement of a mitogen-activated protein kinase signaling pathway in the regulation of urokinase promoter activity by c-Ha-fas
23. Induction of Mr 92,000 type IV collagenase expression in a squamous cell carcinoma cell line by fibroblasts
24. Rac1 in human breast cancer: Overexpression, mutation analysis, and characterization of a new isoform, Rac1b
25. High levels of tissue inhibitor of metalloproteinase-2 (TIMP-2) expression are associated with poor outcome in invasive bladder cancer
26. Cellular distribution of 92-kd type IV collagenase/gelatinase B in human hepatocellular carcinoma
27. Clinical significance of α-catenin, collagen IV, and Ki-67 expression in epithelial ovarian cancer
28. Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystadenocarcinomas: Clinical and prognostic implications
29. 72-Kilodalton type IV collagenase, type IV collagen, and Ki67 antigen in serous tumors of the ovary: A clinicopathologic, immunohistochemical, and serological study
30. Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma
31. Increased type-IV collagenase (MMP-2 and MMP-9) activity following preoperative radiotherapy in rectal cancer
32. Extrinsic regulators of epithelial tumor progression: Metalloproteinases
33. Activity of type IV collagenases in benign and malignant breast disease
34. Localization of the 92 kd gelatinase mRNA in squamous cell and adenocarcinoma of the lung using in situ hybridization
35. Control of type IV collagenase activity by components of the urokinase-plasmin system: A regulatory mechanism with cell-bound reactants
36. High affinity binding of latent matrix metalloproteinase-9 to the α2(IV) chain of collagen IV
37. Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion
38. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice beating human ovarian carcinoma xenografts